(MENAFN- Market Press Release) November 3, 2025 12:10 am - The global Interleukin (IL)-12/23 Inhibitors for Crohn's Disease Market is valued at USD 4,150 million in 2025 and projected to grow at a 10.8% CAGR through 2032.

Interleukin (IL)-12/23 Inhibitors for Crohn's Disease Market to Reach USD 4,150 Million by 2025, Growing at a CAGR of 10.8% Through 2032

The global Interleukin (IL)-12/23 Inhibitors for Crohn's Disease Market is witnessing robust growth, driven by rising incidences of inflammatory bowel disease (IBD), the expanding adoption of biologic therapies, and increasing awareness of advanced immunomodulatory treatments. Valued at USD 4,150 million in 2025, the market is projected to grow at a compound annual growth rate (CAGR) of 10.8% between 2025 and 2032, supported by strong research and development pipelines, expanding patient access programs, and favorable reimbursement policies. North America leads the market, followed by Europe and the Asia-Pacific region, where growing healthcare investments and biosimilar entry are accelerating adoption.

The demand for IL-12/23 inhibitors is primarily fueled by their proven efficacy in moderating immune system response and reducing intestinal inflammation in Crohn's disease patients. Rapid technological advancements in monoclonal antibody production and precision medicine are further shaping the treatment landscape. Additionally, increasing clinical success of next-generation inhibitors such as ustekinumab and guselkumab is reinforcing market expansion, particularly across developed healthcare systems.

Key Segment and Application Insights

The market is segmented by drug type, route of administration, and end-user. Among these, monoclonal antibody-based IL-12/23 inhibitors dominate due to their targeted mechanism of action and higher efficacy rates compared to conventional therapies. Parenteral formulations remain the preferred route, accounting for a significant revenue share, supported by enhanced patient adherence and improved pharmacokinetics. Hospital pharmacies and specialty clinics continue to serve as key distribution channels, driven by increasing biologic therapy usage and patient monitoring needs. Moreover, ongoing research into subcutaneous and oral formulations is expected to unlock new growth opportunities in the coming years.

Price Trend Overview

The average price of IL-12/23 inhibitors observed a moderate rise of 3.5–4% between 2024 and 2025, primarily across major markets such as the United States, Germany, and Japan. This increase was attributed to higher production costs, ongoing supply chain adjustments post-pandemic, and inflationary pressures on biologic raw materials. However, the entry of biosimilar products and competitive pricing strategies by key manufacturers are expected to stabilize prices beyond 2026. North America remains the highest-priced market due to advanced clinical infrastructure and reimbursement benefits, while Asia-Pacific is emerging as a cost-efficient manufacturing hub.

Key Players Snapshot

Leading companies in the global Interleukin (IL)-12/23 inhibitors landscape include Johnson & Johnson (U.S.), AbbVie Inc. (U.S.), Merck & Co. (U.S.), Eli Lilly and Company (U.S.), and Novartis AG (Switzerland). These firms dominate through strong portfolios of approved biologics and active clinical pipelines targeting Crohn's disease and related autoimmune disorders. Emerging players in Japan, South Korea, and India are focusing on biosimilar development and collaborative research initiatives to strengthen their foothold in this rapidly expanding therapeutic segment.

Request for customization

MENAFN04112025003520003262ID1110290760